Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Morphosys AG announces European patent grant for cancer compound MOR20
Morphosys AG:Says that the European Patent Office has granted a patent covering the company's cancer compound MOR20.Says the new patent (EP2383297) covers the antibody's protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same.Says the new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.
Latest Key Developments in Biotechnology
- Omeros Corp prices $35.0 million public offering of common stock
- Navidea Biopharmaceuticals Inc announces presentation of Lymphoseek three-year recurrence and survival outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and Melanoma
- Algeta appoints Thomas Ramdahl as new Managing Director
- Algeta ASA appoints chairman; to apply for delisting of shares from Oslo Stock Exchange
- Share this
- Digg this